MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Indeglitazar

CAS No. : 835619-41-5

MCE 国际站：Indeglitazar

产品活性：Indeglitazar (PPM 204) 是一种具有口服活性的 PPAR 泛激动剂，对 PPARα，PPARδ 和 PPARγ 都有作用活性。

研究领域：Cell Cycle/DNA Damage  |  Vitamin D Related/Nuclear Receptor

作用靶点：PPAR

In Vitro: In an assay of preadipocyte differentiation, measuring in part functional insulin sensitization capability of the cells, Indeglitazar shows an EC₅₀ of 0.32 μM compared with Rosiglitazone, which shows an EC₅₀ of 13 nM, although the maximal response obtained from the 2 compounds is comparable.

In Vivo: An initial assessment of in vivo activity is carried out using the Zucker rat model of diabetes. The significant lowering of glucose, HbA_1C, triglycerides, and total cholesterol are observed after i.v. treatment with 10 mg/kg Indeglitazar once per day for 3 weeks. Notably, the level of Adiponectin (on day 21) is essentially unchanged in treated vs. untreated animals (4.8 mcg/mL vs. 4.9 mcg/mL), thus the observed reductions in glucose and HbA_1C are achieved in an adiponectin-independent fashion. These differences in the effects of Indeglitazar in vivo may be a consequence of synergy between the 3 PPAR activities or because of the SPPARM profile of the compound, or a combination of these factors. The oral activity of Indeglitazar is assessed in the ob/ob model of diabetes and insulin resistance. Indeglitazar significantly decreases glucose, insulin, triglycerides, and free fatty acid levels.

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Cell Cycle/DNA Damage Compound Library  |  Clinical Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Anti-diabetic Compound Library  |  Anti-COVID-19 Compound Library  |  Orally Active Compound Library  |  Anti-Obesity Compound Library  |  Transcription Factor-Targeted Library  |  Lipid Metabolism Compound Library   |  Antidepressant Compound Library  |  Nuclear Receptor Compound Library  |  Osteogenesis Compound Library  |  Cancer Stem Cells Compound Library  |  Mitochondrial Protection Compound Library  |  LY518674  |  Bocidelpar  |  Retinoic acid  |  5-Aminosalicylic Acid-d₃ hydrochloride  |  Naveglitazar  |  Ertiprotafib  |  ATRA-biotin  |  Convallatoxin  |  MHY908  |  Ciprofibrate  |  MK-886  |  Bezafibrate-d₄  |  Mifobate  |  10-Nitrolinoleic acid  |  Magnolol  |  PPAR agonist 1  |  PTGR2-IN-1  |  GW1929 hydrochloride  |  Astaxanthin  |  H-​Trp-​Glu-​OH  |  Fmoc-leucine  |  PPARγ agonist 2  |  GSK0660  |  Pparδ agonist 1  |  MA-0204  |  Saroglitazar  |  Edaglitazone  |  Elafibranor  |  Mavodelpar

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

货号: HY-14817

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。